Resources
Life Saving Drugs Program – Gaucher disease (type 1) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Gaucher disease (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break.
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type VI (MPS VI) under the Life Saving Drugs Program.
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type IVA (MPS IVA) under the Life Saving Drugs Program.
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type II (MPS II) under the Life Saving Drugs Program.
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type I (MPS I) under the Life Saving Drugs Program.
Life Saving Drugs Program – Pompe disease – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for infantile-onset or late-onset Pompe disease under the Life Saving Drugs Program.
Life Saving Drugs Program – Late infantile Batten disease (CLN2)
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for late-infantile onset Batten disease under the Life Saving Drugs Program.
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for hereditary tyrosinaemia (type 1) under the Life Saving Drugs Program.
Life Saving Drugs Program – Gaucher disease (type 1) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for Gaucher disease (type 1) under the Life Saving Drugs Program.
Life Saving Drugs Program – Late infantile Batten disease (CLN2 disease) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Batten disease for the first time, or after a break.
Life Saving Drugs Program – Fabry disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Fabry disease.
Life Saving Drugs Program – Fabry disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Fabry disease for the first time, or after a break.
Better Renal Services Steering Committee communique – 15 July 2024
An update from the Better Renal Services Steering Committee after their meeting on 15 July 2024.
New arrangements for migalastat (Galafold®) – information for prescribers
This fact sheet is for current prescribers (treating physicians) with patients requiring treatment for Fabry disease. It explains how a treatment for this condition, migalastat (Galafold®), will be transitioning from the Life Saving Drugs Program to the PBS.
New arrangements for migalastat (Galafold®) for treatment of Fabry Disease
This fact sheet is for current and future patients with Fabry disease explaining how a treatment for this condition, migalastat (Galafold®), will be transitioning from the Life Saving Drugs Program to the PBS. It provides further clarity on future access arrangements via the PBS.
Better Renal Services Steering Committee communique – 26 June 2024
An update from the Better Renal Services Steering Committee after their meeting on 26 June 2024.
Newborn bloodspot screening expansion – Readiness assessment executive summary
This publication outlines the key findings of the national readiness assessment conducted in 2023. The aim of the readiness assessment is to understand how NBS programs operate nationally. It also looks at critical factors for achieving consistency and expanding the number of conditions screened.
Better Renal Services Steering Committee communique – 8 May 2024
An update from the Better Renal Services Steering Committee after their meeting on 8 May 2024.
Review of the National Strategic Framework for chronic conditions
In September 2023, we engaged Ernst & Young to conduct a review of the National Strategic Framework for chronic conditions, its related action plans and the National Asthma Strategy 2018.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 28 June 2024
Life Saving Drugs Program (LSDP) Expert Panel agenda for the 18th meeting on 28 June 2024.
Renal facility design guidelines for remote areas
Renal facility design guidelines developed to inform the infrastructure builds of the renal dialysis units under the Better Renal Services for First Nations People Budget Measure.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 16 April 2024
This communique provides a summary of the advisory committee's meeting on 16 April 2024.
40:53
Community Dialysis Unit Expression of Interest information webinar – 18 March 2024
Webinar held on 18 March 2024, hosted by the National Aboriginal Community Controlled Health Organisation (NACCHO) and the Department of Health and Aged Care. The webinar focussed on improving access to dialysis treatments for First Nations Australians in remote communities.
Community Dialysis Unit Expression of Interest – fact sheet and FAQs
We are funding 30 dialysis units to provide life-saving health care for First Nations Australians with kidney disease. Communities are invited to self-identify dialysis need through an EOI process, as outlined by this fact sheet.
Date last updated: